Good Review Practices IND guidance ready for dissemination within FDA -- CBER's Schwieterman.
IND GOOD REVIEW PRACTICES DRAFT GUIDANCE READY FOR DISSEMINATION WITHIN FDA, Center for Biologics Evaluation & Research Immunology & Infectious Disease Branch Chief William Schwieterman, MD, a member of the guidance committee, told the University of Texas' International Industrial Pharmacy conference in Austin on Feb. 26. The IND GRP document "should come out this year," Center for Drug Evaluation & Research Director Janet Woodcock, MD, predicted at the IIPC meeting. Schwieterman noted that FDA will eventually seek industry input into the document.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth